Transgene files 2 patents for liver and breast cancer drugs Transgene Biotek has filed 2 patents for its cancer drug technologies based on its proprietary RNAi platform. The first patent, for a liver cancer drug was filed following excellent results demonstrated in the latest animal studies and it covers a novel technology that employs an AAV vector system genetically modified by Transgene to efficiently express specific microRNA that silence a particular metastasis-promoting gene in liver cancer cells. Liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality.The second patent, for a breast cancer drug describes another novel technology developed by Transgene that employs an efficient system which expresses short interfering RNA cloned in a viral vector that silence a particular metastasis-promoting gene in breast cancer cells. This drug is specifically designed not only to treat primary breast cancer but also to fight against potential metastafic tumours. Worldwide, breast cancer is the most common cancer in women, representing 16% of all female cancers, and causes well over 5 lakh deaths annually. This patent was also filed following exciting results in recent animal studies.The company made this announcement during the trading hours today, 03 March 2010.